1 2	NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
3	Guideline scope
4	Renal and ureteric stones: assessment and
5	management
6 7	The Department of Health in England has asked NICE to develop a clinical guideline on assessing and managing renal stones.
8 9	The guideline will be developed using the methods and processes outlined in <u>Developing NICE guidelines: the manual</u> .
10 11	This guideline will also be used to develop the NICE quality standard for renal stones.
12	1 Why the guideline is needed
13	Key facts and figures
14	Renal and ureteric stones (urolithiasis) are a major clinical and economic
15	burden to the NHS. Hereafter, the term 'renal stones' should be taken to
16	include ureteric stones. Epidemiological data suggest that the incidence and
17	prevalence of renal stones is increasing. The number of hospital episodes
18 19	increased by 70% over a 15-year period between 2000 and 2015, from 51,035 episodes to 86,742 episodes (Hospital Episode Statistics (HES) data). The
20	lifetime prevalence of renal stone disease is 13%. Consequently, the direct
21	costs of treatment are increasing as well as the indirect socioeconomic
22	burdens of reduced quality of life, sickness leave and medical follow-up.
23	

DRAFT

24 Current practice

25 Renal stones usually present as an acute episode with severe pain, although

some stones are picked up incidentally during imaging or may present as a

history of infection. The initial diagnosis is made by taking a clinical history,

28 conducting a clinical examination and carrying out imaging; initial

29 management is with painkillers and treatment of any infection.

30 Ongoing treatment of renal stones depends on the site of the stone and size 31 of the stone (<10 mm, 10 to 20 mm, greater than 20 mm; staghorn stones). 32 Options for treatment range from observation with pain relief to surgical 33 intervention. Available interventions include extracorporeal shockwave 34 lithotripsy (ESWL), ureteroscopy and percutaneous stone removal (surgery). 35 As well as the site and size of the stone, treatment also depends on local 36 facilities and expertise. Most centres have access to ESWL, but some use a 37 mobile machine on a sessional basis rather than a fixed site machine with 38 easier access during the work week. The use of a mobile machine may affect 39 options for emergency treatment, but may also add to waiting times for non-40 emergency treatment. Although surgery for renal stones (ureteroscopy) is 41 increasing (there has been a 49% increase from 12,062 treatments 2009-42 2010, to 18,066 in 2014-2015 (HES data) there is trend towards day-43 case/ambulatory care, increasing by 10% to 31,000 cases per annum 44 between 2010-2015. The total number of bed days used for renal stone 45 disease has fallen by 15% since 2009-2010. However, waiting times for 46 treatment are increasing and this means that patient satisfaction is likely to be 47 lower.

48

Because the incidence of renal stones and the rate of intervention are
increasing, there is a need to reduce recurrences through patient education
and lifestyle changes. Assessing dietary factors and changing lifestyle have
been shown to reduce the number of episodes in people with renal stone
disease.

54 **2** Who the guideline is for

- 55 People using services, their families and carers, and the public will be able to
- ⁵⁶ use the guideline to find out more about what NICE recommends, and help
- 57 them make decisions.
- 58 This guideline is for:
- 59 People with renal stones, their families and carers
- 60 Healthcare professionals
- Clinical commissioning groups.
- 62 NICE guidelines cover health and care in England. Decisions on how they
- 63 apply in other UK countries are made by ministers in the Welsh Government,
- 64 <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>.

65 **Equality considerations**

- 66 NICE has carried out an equality impact assessment [add hyperlink in final
- 67 version] during scoping. The assessment:
- lists equality issues identified, and how they have been addressed
- explains why any groups are excluded from the scope.
- 70 The guideline will look at inequalities relating to the availability of extra
- 71 corporeal shockwave lithotripsy (ESWL) treatment. Fixed site lithotriptors are
- currently limited to a few urology centres requiring some people to travel
- 73 distances for treatment. Other units may hire mobile ESWL lithotriptors but
- this may mean longer waiting times for treatment. The guideline will also look
- at the risk to women of childbearing age of radiation exposure during imaging.

76 **3** What the guideline will cover

77 **3.1** Who is the focus?

78 Groups that will be covered

- People with renal stones (kidney and ureteric stones)
- Specific subgroups of people identified as needing specific consideration
 include pregnant women.

82 **3.2** Settings

83 Settings that will be covered

• All settings in which NHS-commissioned care is provided.

85 **3.3** Activities, services or aspects of care

86 Key areas that will be covered

- 87 We will look at evidence in the areas below when developing the guideline,
- 88 but it may not be possible to make recommendations in all the areas.
- Imaging for diagnosing and assessing renal stones (for example, CT,
 ultrasound)
- 91 2 Pharmacological management of pain in people with symptomatic renal 92 stones (for example, non-steroidal anti-inflammatory drugs, opioids)
- 93 3 Surgical interventions for symptomatic renal stones (for example, for
- 94 upper and lower pole renal stones, upper and lower ureteric stones)
- 95 4 Managing asymptomatic renal stones [for example, extracorporeal
- 96 shockwave lithotripsy (ESWL), ureteroscopy, percutaneous surgery]
- 97 5 Follow-up management in people who have had renal stones
- 98 Imaging
- 99 Metabolic investigations (for example, stone analysis, urinalysis, blood
 100 tests)

- 101 Pharmacological treatment for people without clear metabolic results (for
- 102 example, thiazide diuretics)
- 103 Dietary interventions
- 104 Lifestyle interventions (for example, weight loss and exercise).

105 Areas that will not be covered

- 106 1 Bladder stones
- 107 2 Open surgery for renal (kidney and ureteric) stones.

108 Related NICE guidance

- 109 Laparoscopic nephrolithotomy and pyelolithotomy (2007) NICE
- 110 interventional procedure guidance 212

111 NICE guidance about the experience of people using NHS services

- 112 NICE has produced the following guidance on the experience of people using
- 113 the NHS. This guideline will not include additional recommendations on these
- 114 topics unless there are specific issues related to renal stones:
- 115 Medicines optimisation (2015) NICE guideline NG5
- 116 Patient experience in adult NHS services (2012) NICE guideline CG138
- 117 <u>Service user experience in adult mental health</u> (2011) NICE guideline
- 118 CG136
- 119 Medicines adherence (2009) NICE guideline CG76
- 120 **3.4** *Economic aspects*
- 121 We will take economic aspects into account when making recommendations.
- 122 We will develop an economic plan that states for each review question (or key
- 123 area in the scope) whether economic considerations are relevant, and if so
- 124 whether this is an area that should be prioritised for economic modelling and
- 125 analysis. We will review the economic evidence and carry out economic
- 126 analyses, using an NHS and personal social services (PSS) perspective.

3.5 Key issues and questions 127 While writing this scope, we have identified the following key issues, and key 128 129 questions related to them: 130 1 Imaging for diagnosing and assessing renal stones 131 1.1 What is the most clinically and cost-effective diagnostic imaging 132 technique for people with suspected renal stones? 133 Pharmacological management of pain in people with symptomatic 2 134 renal stones 135 2.1 What are the most clinical and cost-effective drugs for managing 136 pain in people with symptomatic renal stones? 137 3 Surgical intervention for symptomatic renal stones 138 3.1 What is the most clinically and cost-effective length of time to 139 manage symptomatic renal stones conservatively before active intervention? 140 3.2 What are the most clinically and cost-effective options for surgical 141 142 treatment of symptomatic renal stones? 143 4 Managing asymptomatic renal stones 144 4.1 What is the most clinically and cost-effective management (for 145 example, ESWL, ureteroscopy) of asymptomatic renal stones? 146 Follow-up management in people who have had renal stones 5 147 5.1 What is the clinical and cost-effectiveness of performing imaging for follow-up in people who have had renal stones? 148 149 5.2 Which metabolic investigations, if any, should be performed for people who have had renal stones? 150 151 5.3 What are the most clinically and cost-effective pharmacological 152 treatments to reduce the risk of future stones in people who have had 153 renal stones? 154 5.4 What is the clinical and cost-effectiveness of dietary and other 155 lifestyle interventions to reduce the risk of future stones in people who 156 have had renal stones?

- 157 The key questions may be used to develop more detailed review questions,
- 158 which guide the systematic review of the literature.

159 **3.6** *Main outcomes*

- 160 The main outcomes that will be considered when searching for and assessing
- 161 the evidence are:
- 162 1 Quality of life
- 163 2 Stone-free rate
- 164 3 Recurrence rate
- 165 4 Mortality
- 166 5 Pain intensity
- 167 6 Adverse events
- 168 7 Use of healthcare services (including re-admission rates following169 interventions)
- 170 8 Kidney function

171 4 NICE quality standards and NICE Pathways

- 172 4.1 NICE quality standards
- 173 NICE quality standards that may use this guideline as an evidence


174 source when they are being developed

• Renal stones. NICE quality standard. Publication date to be confirmed

176 4.2 NICE Pathways

- 177 NICE Pathways bring together all related NICE guidance and associated
- 178 products on a topic in an interactive topic-based flow chart. When this
- 179 guideline is published, the recommendations will be added to NICE Pathways.
- 180 Other relevant NICE guidance will also be added to the Pathway, including:
- 181 Laparoscopic nephrolithotomy and pyelolithotomy (2007) NICE
- 182 interventional procedures guidance 212

- A draft pathway outline on renal stones, based on the draft scope, is included 183
- 184 below. It will be adapted and more detail added as the recommendations are
- written during guideline development. 185



187

188 5 Further information

This is the draft scope for consultation with registered stakeholders. The consultation dates are 20 January to 17 February 2017.

The guideline is expected to be published in February 2019.

You can follow progress of the guideline.

Our website has information about how <u>NICE guidelines</u> are developed.

189